Highest-materiality recent filing
Equity plan amended to increase authorized shares by 500,000 to 3,175,000; approved with 994,315 votes for.
TAO Synergies raises $11M in private placement; terminates Alkon agreement; appoints Vice-Chairman
Sold 11,000 Series E convertible preferred shares ($1,000 stated value) and warrants for 1.375M common shares at $8.00; $11M gross proceeds.
Joseph Jacks, co-founder/CEO of Latent Holdings and early Bittensor pioneer, engaged as advisor to digital asset treasury strategy led by James Altucher.
TAOX shareholders approve 20%+ share issuance and 2M-share equity plan increase
Special meeting held Aug 6, 2025; 567,847 shares (35.23%) represented, quorum achieved.
TAO Synergies accumulates 42,111 Bittensor (TAO) tokens as part of DeAI treasury strategy
As of Aug 5, 2025, holds 42,111 TAO tokens acquired via purchases and staking.
TAO Synergies acquires $10M in TAO tokens, becoming largest public pure play holder
Acquired 29,899 TAO tokens for $10M at avg ~$334/token as of July 17, 2025.
Synaptogenix rebrands to TAO Synergies, shifts to AI-focused crypto treasury with staking
Name changed to TAO Synergies Inc. effective June 26, 2025; ticker to change from SNPX to TAOX on July 1.
Synaptogenix buys TAO, hires BitGo for custody/staking, begins staking yield
Initial purchase of TAO under crypto treasury strategy focused on AI and machine learning.
Synaptogenix launches crypto treasury strategy focused on Bittensor TAO, raises $5.5M
Plans initial $10M acquisition of TAO tokens (over 2x market cap); long-term target of $100M.
On June 8, 2025, Dr. Alan J. Tuchman resigned as Chief Executive Officer and director of the Company, effective June 8, 2025. Dr. Tuchman will serve as Chief Medical Officer of the Company.
On June 4, 2025, Dr. Daniel L. Alkon resigned as an officer, director and Chief Science Officer of the Company to become a consultant working with the Company’s newly established Bryostatin Development Committee
On June 6, 2025, Mr. Joshua Silverman was appointed as Executive Chairman of the Company’s board of directors and in consideration of his new role, Mr. Silverman will be paid a monthly salary of $30,000 per month.
Max materiality 0.90 · Median 0.65 · Most common event other_material